Skip to main content

Progress in the Developement of Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

The metabotropic glutamate type 2 (mGlu2) receptor is a G-protein coupled receptor (GPCR) expressed on presynaptic nerve terminals where it negatively modulates glutamate and GABA release. Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclinical animal models of anxiety and schizophrenia. Clinical work with LY354740 demonstrated activity in a CO2 inhalation study suggesting application in the treatment of anxiety related disorders. Subsequently, a related prodrug LY2140023 demonstrated improvements in positive and negative symptoms in patients suffering from schizophrenia. These molecules exhibit combined mGlu2/mGlu3 activity although there is evidence from knock-out studies that preclinical anti-psychotic effects may be mediated via the mGlu2 receptor. An alternative avenue for modulating GPCRs is to act via allosteric mechanisms, binding at a different site from the orthosteric agonist. Since the first discovery of mGlu2 positive allosteric modulators (PAMs) such as 2,2,2-TEMPS and BINA, multiple families of mGlu2 modulators have been reported and several have entered into clinical development. This review focuses on recent advances in the development of novel mGlu2 PAMs by analysis of compounds disclosed in research articles and patent literature between 2007 and 2010.





Keywords: ALLOSTERIC MODULATORS; Acetophenones; Allosteric; Benzimidazoles; Cyclic Carbamates; Glutamate; Imidazopyridines; Isoindolones; Oxazolobenzimidazoles; PAM; Pharmaceuticals; Prous Science Integrity; Pyridones; acetophenone; acyclic acetophenones; affinity modulation; agonism; agonistic drugs; alkyls; amino acid like; amphetamine; antidepressant; antipsychotic; antipsychotic activity; antipsychotic effects; anxiety; anxiolytic; anxiolytic activity; anxiolytic effects; asymmetric; asymmetric center; bioisosteric; chemotypes; chirality; cyclic carbamate; efficacy; electrostatic; halogens; hippocampus; incubation; ionotropic glutamate (iGlu); isoindolone derivatives; lipophilic; lipophilic substituents; mGlu; mGluR; metabotropic glutamate receptor; microsomes; modulator; molecular weight; nanomolar activity; nanomolar potent; nervous system (CNS); neurotransmitter; oxazolidinone; oxazolobenzimidazoles; patent; pathophysiology; polarity; prefrontal cortex; principal component analysis (PCA); prolactin levels; psychiatric disorders; pyrazine; pyrimidone; rationale; receptor signaling; schizophrenia; solubilizing; spirocyclic cyclohexyl group; stereochemistry; synaptic responses; tolerance development; vertebrates

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986711793979706

Publication date: January 1, 2011

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2011/00000018/00000001/art00004
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more